This book investigates and highlights the most critical challenges the pharmaceutical industry faces in an increasingly competitive environment of inflationary R&D investments and tightening cost control pressures. The authors present three sources of pharmaceutical innovation: new management methods in the drug development pipeline; new technologies as enablers for cutting-edge R&D; and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. New models and methods are illustrated with cases from Europe, the US, and Asia. This third fully revised edition was expanded to reflect the latest updates in open and collaborative innovation, the greater strategic importance of venture capital and early-stage investments, and the new range of emerging technologies now being put to use in pharmaceutical innovation.

Health care innovation is possibly the greatest opportunity and challenge of our generation. This important book shows how pharmaceutical companies will continue to play an instrument role in making our lives better.

Very comprehensive review and analysis of current challenges for the biopharmaceutical industry. To stay competitive in this new technology driven environment, the industry started to develop new partnership models to close the innovation gap and provide patients with the relevant healthcare toolkits at the convergence of pharmaceuticals, diagnostics and IT technologies. Very exciting times ahead well depicted in this book!

Great. The 3rd edition is not only an update. It’s an outstandingly featured summary on the challenges of pharma innovation.

Eckard von Keutz, SVP and Head of Early Development, Bayer Healthcare

“Very comprehensive review and analysis of current challenges for the biopharmaceutical industry. To stay competitive in this new technology driven environment, the industry started to develop new partnership models to close the innovation gap and provide patients with the relevant healthcare toolkits at the convergence of pharmaceuticals, diagnostics and IT technologies. Very exciting times ahead well depicted in this book!” (Karima Boubekeur, VP Emerging Portfolio and Search & Evaluation, AstraZeneca)

“Great. The 3rd edition is not only an update. It’s an outstandingly featured summary on the challenges of pharma innovation.” (Eckard von Keutz, SVP and Headof Early Development, Bayer Healthcare)

“…a profoundly researched and comprehensively illustrated creation of the value-drivers of pharmaceutical innovation.” (Florian Gantner, VP Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim)

“’Leading Pharmaceutical Innovation’ is the benchmark on pharmaceutical innovation management.” (Alexander Musil, CFO Takeda Mexico)

“Globalization, internationalization and open innovation are three major trends in the industry. Gassmann, Schuhmacher, von Zedtwitz and Reepmeyer provide most valuable insights in these topics. I highly recommend reading this book.” (Mathias Schmidt, CEO Armagen)

“I recommend this new book to pharma managers and researchers in this industry.” (Maximilian von Wuelfing, General Manager Mylan BeLux)

“This text is an excellent information source for innovation concepts in the modern era when pharma productivity is getting ever challenging in this global environment.” (Praveen Tyle, Executive Vice President R&D, Lexicon Pharmaceuticals)

“The book remains the key important publication of pharmaceutical innovation for business executives, scientists and students. The 3rd edition was updated especially regarding innovation alliances and addresses the key challenges that pharmaceutical R&D is facing nowadays.” (Katharina Caspary, Director Pharmacovigilance, Horizon Pharma)

“Excellent book for strategies on the management of pharma innovation. Highly recommendable for creating the bigger picture and new perspectives for action.” (Ingo Gaida, Head of IT Operations R&D, Bayer Business Services)

“Analytical & critical - a "spot on" review of the constantly changing pharma environment.” (Guenther Forster, former SVP Medical Development & Strategies, MerckSerono)

“This great book helps to understand the complexity of the challenges the pharmaceutical industry is facing.” (Ingo Henes, SVP Human Relations at Rentschler Biotechnologie)